🎄Holiday Notice: Shipping for temperature-sensitive medications (Ozempic, Mounjaro, etc.) is paused. Service resumes Monday, Dec 29.
Generic Semaglutide Now Available!
We Ship To The U.S. Only
Call Toll Free:
A new obesity drug may be approved by the end of 2025. The new medication—“CagriSema”—is manufactured by Novo Nordisk and has shown promising results in trials for type 2 diabetes treatment and weight loss. CagriSema can be a life-changing alternative to other similar GLP-1 medications if all goes to plan. It recently finished the first of four parts of Phase III trials.
10% OFF
On Your First Order
Copy Code
MYRX10
CagriSema is made of cagrilintide and semaglutide. Semaglutide and cagrilintide are two medications made for the treatment of obesity and type 2 diabetes. It is considered a “dual-acting” therapy. CagriSema is still being tested before it is submitted for FDA approval.
Semaglutide is a GLP-1RA and cagrilintide is a long-acting amylin. Both medications mimic naturally occurring hormones. They help with things like suppressing appetite and slowing gastric emptying. Semaglutide further helps with increasing insulin production and reducing glucagon secretion.
Trials—so far—have found that CagriSema has many benefits for people with type 2 diabetes. One of the main benefits is how it can improve blood sugar control. Studies found that CagriSema helps lower blood sugar levels and reduces HbA1c—an important measure of long-term blood sugar. It works better than the two medications it’s made from when taken separately. Animal studies also suggest that CagriSema helps muscle tissues take in more glucose. This could also contribute to better long-term glycemic control.
Studies consistently showed that CagriSema could also help patients lose more than 22% of their weight. It does this by reducing patients’ appetite and slowing down their stomach emptying. This medication also helps with weight loss by regulating the patient’s glucose and increasing insulin levels. The semaglutide and cagrilintide combination amplify these effects. Many other similar medications—such as other semaglutide medications—have more limited results and capabilities. It could also be a more complex treatment method to take multiple medications when one dual medication may have the same effect with fewer complications.
Novo Nordisk recently announced headline results from REDEFINE 1—a phase 3 trial investigating CagriSema in adults with obesity or overweight with at least one related health issue. The trial included 3,417 people who met this criteria. This 68-week trial announced it was finished in late December of 2024. This trial compared CagriSema to equal doses of cagrilintide and semaglutide that were taken once per week. They also tested a placebo medication.
CagriSema is particularly geared toward those who are struggling with glycemic control with standard therapies. It is also for patients who struggle with obesity or overweight-related health conditions. The high amounts of weight loss linked CagriSema could also make it a non-surgical alternative for some patients who might otherwise require bariatric surgery. It is known to have fewer side effects than other similar medications. It may also be able to reduce the amount of medications patients have to take.
Research is being done to see how CagriSema affects heart health and other health factors over 4.5 years. Investigating its impact on liver, thyroid, and kidney functions could open up new possibilities for its role in metabolic health management.
Most of the reported side effects for CagriSema have been gastrointestinal related. Most of these side effects resolve in 2-8 days. Some of the usual side effects that patients experience are:
Semaglutide has similar side effects to CagriSema when used by itself. It can also cause abdominal pain or more serious side effects (in rare cases). Semaglutide can cause serious complications. This usually only happens to less than 2% of patients taking the medication. This may include pancreatitis or gallbladder disease. It could also cause acute kidney injury in some patients and diabetic retinopathy complications. CagriSema has shown far less complications in studies so far.
Cagrilintide alone has been known to cause similar side effects to the ones experienced with CagriSema. It could also cause fatigue or reactions at the site of the injection. Some patients may also build up anti-drug antibodies. This usually only happens after the medication has been taken for an extended period of time. CagriSema and related drugs should only be used under medical supervision to minimize side effects.
CagriSema is still being studied in the REDEFINE program. The trial results show a 22.7% weight loss after 68 weeks. They also have shown a 2.2% HbA1c reduction. CagriSema has not been FDA-approved. Submissions for approval are expected to take place in late 2025 when testing is completed.
CagriSema might change type 2 diabetes treatment in 2026. This medication could become a new first-line choice for providers whose patients struggle with diabetes and need help with weight loss treatment. CagriSema might also speed up the creation of other multi-agonist treatments. It could make combination therapies the preferred method for managing complex metabolic diseases.
CagriSema is a new treatment that may start being seen by next year. It could open up the treatment options available for patients with obesity and type 2 diabetes. CagriSema helps with weight loss and blood sugar control. It may also be safer and work more effectively than current options. Patients should talk to their medical providers to learn more about their treatment options.
Visit MyRx Outlet to purchase affordable weight loss medication from Canada.
Clinical studies have shown that CagriSema—a combination of semaglutide and cagrilintide—leads to more weight loss than either of its ingredients when they are used alone. CagriSema led to 22.7% weight loss. Cagrilitntide (11.8%) and semaglutide (16.1%) showed much less.
CagriSema has not yet been approved for public use. It is still being tested.
CagriSema has not been submitted for approval yet. It could be by the end of 2025. It could start appearing on the market as early as 2026.
CagriSema is currently in Phase 3 of clinical trials. It is in the final parts of the REDEFINE trial—a trial focusing on type 2 diabetes treatment.
Written & Reviewed By
The MyRx Team
The MyRx Outlet team is a dedicated group of healthcare professionals and pharmacists dedicated to delivering up-to-date and accurate information on medications and key healthcare topics. With years of experience in the healthcare field, our team is passionate about supporting individuals in reaching their health and wellness goals through our articles.
The information provided here is for educational purposes only and is not intended to serve as medical advice, diagnosis, or treatment recommendations. It should not be taken as an endorsement of any specific medication or treatment. Individual health conditions and responses to treatment can vary greatly; therefore, this information should not be seen as a guarantee of safety, suitability, or effectiveness for any particular individual. Always consult with a healthcare professional for personalized medical advice and before making any decisions regarding your health or treatment plans.
Related Articles
Learn what compounded tirzepatide is, how it differs from Mounjaro and Zepbound, and what to know about its safety, cost, and FDA regulations.
Learn how to store Wegovy safely. Find out when to refrigerate, how long it lasts at room temperature, and tips for traveling with your medication.
Compare Rybelsus vs. Ozempic for type 2 diabetes and weight loss. Learn about key differences, side effects, and which medication may be right for you.
Share:
